¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå : Áúȯº°, À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - ¼¼°è »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Viral Vector Vaccines Market, By Disease, By Type, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1781961
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 269 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,544,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,502,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,900,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 8¾ï 5,043¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2032³â¿¡ CAGR 15.93%·Î È®´ë

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ½ÃÀå ¿ªÇÐ

Àü¿°º´ È®»ê Áõ°¡·Î ½ÃÀå ¼ö¿ä Áõ°¡

COVID-19, µ¶°¨, °£¿° µî °¨¿°¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡·Î È¿°úÀûÀÎ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¹é½ÅÀº ¿¬°£ 200¸¸-300¸¸ ¸íÀÇ »ç¸ÁÀ» ¿¹¹æÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è º¸°Ç¿¡¼­ ¹é½ÅÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯Àü°øÇÐÀÇ ²÷ÀÓ¾ø´Â ¹ßÀüÀº º¸´Ù È¿À²ÀûÀÎ ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª µå¹°Áö¸¸ ºÎÀÛ¿ëÀÌ º¸°íµÇ°í ÀÖÀ¸¸ç, ÀϹÝÀεéÀÌ ÁÖÀúÇϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇÑÆí, °³¹ßµµ»ó±¹Àº ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 15.93%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áúȯº°·Î´Â °¨¿°¼º ÁúȯÀÌ 2024³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.

À¯Çüº°·Î´Â ¾Æµ¥³ë¹ÙÀÌ·¯½º°¡ 2024³â ÁÖ¿ä À¯ÇüÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâ 1À§¸¦ ±â·ÏÇß½À´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ¼¼°è ½ÃÀåÀº Áúº´, À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

Áúȯº°·Î´Â °¨¿°¼º Áúȯ, ¾Ï, À¯Àü¼º Áúȯ, ±âŸ 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. °¨¿°¼º Áúȯ ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ¼¼°è ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå¿¡¼­ ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÁÖ·Î Àü ¼¼°è °¨¿°º´ÀÇ ºÎ´ãÀÌ Å©°í, ¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§ÆûÀÌ °¨¿°º´¿¡ ´ëÇÑ ¹é½Å °³¹ß¿¡¼­ ÀÔÁõµÈ È¿°ú¿¡ ±âÀÎÇÕ´Ï´Ù.

½ÃÀåÀº ¾Æµ¥³ë ¼ö¹Ý ¹ÙÀÌ·¯½º(AAV), ¾Æµ¥³ë ¹ÙÀÌ·¯½º, ·»Ä¡ ¹ÙÀÌ·¯½º, ·¹Æ®·Î ¹ÙÀÌ·¯½º, ±âŸ 5°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ¿¹Ãø ±â°£ Áß ¾Æµ¥³ë¹ÙÀÌ·¯½º ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â ÁÖ·Î ¾Æµ¥³ë¹ÙÀÌ·¯½º°¡ °­ÇÑ ¸é¿ª¿ø¼º, Å« À¯ÀüÀÚ ÆäÀ̷ε带 ¿î¹ÝÇÏ´Â ´É·Â, ½Å¼ÓÇÑ ¹é½Å °³¹ß¿¡ ÀûÇÕÇϹǷΠ³Î¸® »ç¿ëµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

ºÏ¹Ì°¡ Àü ¼¼°è ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÷´ÜÀÎ ÇコÄɾî ÀÎÇÁ¶ó, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, ÁÖ¿ä Á¦¾à»ç ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇコÄɾî ÅõÀÚ Áõ°¡, °¨¿°º´ À¯Çà Áõ°¡, ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ¼¼°è ½ÃÀå¿¡¼­ °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - °æÀï ±¸µµ

È¿°úÀûÀ̰í Áï°¢ÀûÀÎ ¹é½Å¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ¼ö¿ä Áõ°¡´Â ±â¼ú Çõ½Å°ú Àü·«Àû ÅõÀÚÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±â¾÷Àº ±ÞÁõÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ º¤ÅÍ ¼³°è °­È­, ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ °³¼±, Á¦Á¶ ´É·Â È®´ë¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü ¹× Á¤ºÎ±â°ü°úÀÇ Á¦ÈÞ´Â °³¹ß ¹× ÀǾàǰ Çã°¡¸¦ °¡¼ÓÈ­Çϱâ À§ÇØ ÀϹÝÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï °¨¿°º´ ¹é½Å µî °¢»ç´Â Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀ» ´Ù¾çÈ­Çϰí ÀÖ½À´Ï´Ù. ¼¼°è ÀÔÁö¸¦ °­È­Çϰí ÷´Ü ¹é½Å Ç÷§Æû¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇØ Áö¿ªÀû È®Àå ¹× Àμö¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å »ê¾÷ ¿¬±¸

Á¦5Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå ±¸µµ

Á¦7Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - Áúȯº°

Á¦8Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - À¯Çüº°

Á¦9Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - Áö¿ª

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.

Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.

Viral Vector Vaccines Market- Market Dynamics

Increasing prevalence of infectious diseases to propel market demand

The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.

Viral Vector Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)

Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024

Based on Type segmentation, adenovirus was the leading Type in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Vaccines Market- Segmentation Analysis:

The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.

The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.

The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.

Viral Vector Vaccines Market- Geographical Insights

The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.

Viral Vector Vaccines Market- Competitive Landscape:

Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.

Recent Developments:

In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL VIRAL VECTOR VACCINES MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

GLOBAL VIRAL VECTOR VACCINES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL VIRAL VECTOR VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL VIRAL VECTOR VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Viral Vector Vaccines Market Overview

2. Executive Summary

3. Viral Vector Vaccines Key Market Trends

4. Viral Vector Vaccines Industry Study

5. Viral Vector Vaccines Market: Impact of Escalating Geopolitical Tensions

6. Viral Vector Vaccines Market Landscape

7. Viral Vector Vaccines Market - By Disease

8. Viral Vector Vaccines Market - By Type

9. Viral Vector Vaccines Market - By End User

10. Viral Vector Vaccines Market- By Geography

11. Key Vendor Analysis- Viral Vector Vaccines Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â